Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Advances in Antithrombotic Research: From Pharmacological Mechanisms to Innovative Approaches
share announcement

Advances in Antithrombotic Research: From Pharmacological Mechanisms to Innovative Approaches

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 10 August 2024 | Viewed by 14603

Special Issue Editors

Dr. Pierpaolo Di Micco

E-Mail Website
Guest Editor
UOC Medicina, Fatebenefratelli Hospital of Naples, 80131 Naples, Italy
Interests: immunology; vascular medicine; cardiology; infectious disease; neurology; coagulation and clinical laboratory
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Vincenzo Russo

E-Mail Website
Co-Guest Editor
Department of Medical Translational Sciences, University of Campania “Luigi Vanvitelli” – Monaldi Hospital, Via Leonardo Bianchi, 80131 Naples, Italy
Interests: atrial fibrillation; cardiovascular pharmacology; arrhythmic disorders; cardiac pacing; non-vitamin K oral anticoagulants; neuromuscular disorders; muscular dystrophies
Special Issues, Collections and Topics in MDPI journals
Dr. Egidio Imbalzano

E-Mail Website
Co-Guest Editor
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
Interests: clinical cardiology; cardiovascular prevention; metabolism; echocardiography; arterial hypertension
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Thrombotic diseases remain the most common causes of morbidity, mortality, and hospitalizations in Western countries. In the last two decades, improvements in pharmacology and clinical pharmacology have allowed us to develop a stronger tailored therapy for each type of thrombotic or thromboembolic disease. Furthermore, the different stages of thrombotic or thromboembolic diseases require different antithrombotic treatment, with the presence of different drugs focused on the different targets of cells involved in prothrombotic states. Moreover, new targets for antithrombotic drugs have been a focus of research for the next steps in tailored antithrombotic treatments.

In this Special Issue, we invite researchers and experts from diverse disciplines to share their experiences and insights into the multifaceted field of antithrombotic research. Contributions that delve into the fundamental mechanisms of thrombosis, novel drug targets, and innovative strategies for preventing thrombotic events are particularly encouraged. By exploring the full scope of antithrombotic research, this Special Issue aims to chart the evolving landscape of antithrombotic interventions.

We are pleased to invite you to contribute original articles, reviews, and communications. We are looking forward to your contributions to this Special Issue.

Dr. Pierpaolo Di Micco
Prof. Dr. Vincenzo Russo
Dr. Egidio Imbalzano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherothrombosis
  • thromboembolic cardiac embolism
  • unusual site of thrombosis
  • venous thromboembolism
  • thrombophilia
  • acute antithrombotic treatment
  • chronic long-term antithrombotic treatment
  • antithrombotics
  • antiplatelets
  • anticoagulants
  • warfarin
  • heparins
  • low molecular weight heparins
  • direct oral anticoagulants
  • aspirin
  • ticagrelor
  • clopidogrel
  • statins
  • PCSK9 inhibitors
  • immunomodulant therapy
  • evolocumab
  • alirocumab
  • eltrombopag

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 334 KiB  
Review
Statins Effects on Blood Clotting: A Review
by Carmine Siniscalchi, Manuela Basaglia, Michele Riva, Michele Meschi, Tiziana Meschi, Giampiero Castaldo and Pierpaolo Di Micco
Cells 2023, 12(23), 2719; https://doi.org/10.3390/cells12232719 - 27 Nov 2023
Cited by 2 | Viewed by 2216
Abstract
Statins are powerful lipid-lowering drugs that inhibit cholesterol biosynthesis via downregulation of hydroxymethylglutaryl coenzyme-A reductase, which are largely used in patients with or at risk of cardiovascular disease. Available data on thromboembolic disease include primary and secondary prevention as well as bleeding and [...] Read more.
Statins are powerful lipid-lowering drugs that inhibit cholesterol biosynthesis via downregulation of hydroxymethylglutaryl coenzyme-A reductase, which are largely used in patients with or at risk of cardiovascular disease. Available data on thromboembolic disease include primary and secondary prevention as well as bleeding and mortality rates in statin users during anticoagulation for VTE. Experimental studies indicate that statins alter blood clotting at various levels. Statins produce anticoagulant effects via downregulation of tissue factor expression and enhanced endothelial thrombomodulin expression resulting in reduced thrombin generation. Statins impair fibrinogen cleavage and reduce thrombin generation. A reduction of factor V and factor XIII activation has been observed in patients treated with statins. It is postulated that the mechanisms involved are downregulation of factor V and activated factor V, modulation of the protein C pathway and alteration of the tissue factor pathway inhibitor. Clinical and experimental studies have shown that statins exert antiplatelet effects through early and delayed inhibition of platelet activation, adhesion and aggregation. It has been postulated that statin-induced anticoagulant effects can explain, at least partially, a reduction in primary and secondary VTE and death. Evidence supporting the use of statins for prevention of arterial thrombosis-related cardiovascular events is robust, but their role in VTE remains to be further elucidated. In this review, we present biological evidence and experimental data supporting the ability of statins to directly interfere with the clotting system. Full article
(This article belongs to the Special Issue Advances in Antithrombotic Research: From Pharmacological Mechanisms to Innovative Approaches)
17 pages, 525 KiB  
Review
Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications
by Marco Heestermans, Géraldine Poenou, Hind Hamzeh-Cognasse, Fabrice Cognasse and Laurent Bertoletti
Cells 2022, 11(20), 3214; https://doi.org/10.3390/cells11203214 - 13 Oct 2022
Cited by 16 | Viewed by 11512
Abstract
Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent) venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a century, and, nowadays, physicians possess a broad panel of multiple anticoagulants to meet the individual needs of [...] Read more.
Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent) venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a century, and, nowadays, physicians possess a broad panel of multiple anticoagulants to meet the individual needs of a patient. Within this review, we aimed to revise the history of the different anticoagulants that are currently prescribed in the clinic. In addition, we compared their pharmacological properties, medical indications, and the difficulties in implementing new anticoagulants in vulnerable patient populations. Since the introduction of unfractionated heparin in the 1930s, major advances in the mechanistic understanding and the medical use of anticoagulants have allowed for significant improvements to treat VTE patients. However, a new generation of anticoagulants is currently being tested in clinical trials, with the goal of further optimizing medical care. Full article
(This article belongs to the Special Issue Advances in Antithrombotic Research: From Pharmacological Mechanisms to Innovative Approaches)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop